| MYC activation, triggered by the insertion of human papillomavirus DNA sequences, can be an important genetic event in cervical oncogenesis. | cervical, |
| Expression of glial fibrillary acidic protein, vimentin, fibronectin, and N-myc oncoprotein in primary human brain tumor cell explants. | brain, |
| Nonrandom distribution of N-myc oncogene genotypes in neuroblastoma. | neuroblastoma, |
| Together, these results demonstrate that ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway is an important mechanism of oncogenic c-myc activation in pancreatic cancer. | pancreatic, |
| Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. | pancreatic, |
| HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. | colorectal, |
| N-myc oncogene expression and amplification in metastatic lesions of stage IV-S neuroblastoma. | neuroblastoma, |
| WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential. | skin, |
| Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. | neuroectodermal, |
| NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. | leukemia, |
| Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors. | laryngeal, |
| Possible collaboration between c-fos and c-myc proto-oncogene products in in vivo lymphomagenesis. | lymphoma, |
| Lack of mutagenicity and clastogenicity of PNAEmu-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt s lymphoma. | lymphoma, |
| Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. | lung, |
| Involvement of the oncoprotein c-Myc in viral telomerase RNA gene regulation during Marek s disease virus-induced lymphomagenesis. | lymphoma, |
| Deregulated expression of a novel component of TFTC/STAGA histone acetyltransferase complexes, rat SGF29, in hepatocellular carcinoma: possible implication for the oncogenic potential of c-Myc. | liver, |
| Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. | kidney, |
| The peptide nucleic acid targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt s lymphoma lacks immunogenicity: follow-up characterization of PNAEmu-NLS. | lymphoma, |
| Loss of amplification and appearance of a novel translocation site of the c-myc oncogene in HL-60 leukemia cells. | leukemia, |
| A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma. | skin, |